

PTO/SBIOSA (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

Substitute for Form PTO-1449

INFORMATION DISCLOSURE CITATION BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

a conection of information talless it displays	orror intornation unless it displays a valid OMB control number.				
Application Number	09/993,159				
Filing Date	November 5, 2001				
First Named Inventor	T. Lovenberg et al.				
Group Art Unit	1632				
Examiner Name					
Altorney Docket Number	ORT-1528				

Examiner Initials	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
		Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
w		wo	95/11894	A1	The University of Toledo et al.	05-04-1995		\vdash
MN wo	03/004637	A1	Banyu Pharmaceutical Co., Ltd.	01-16-2003				
	٠							_

Examiner's Cite No.¹	NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial; symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published DUGOVIC, C. et al., "Aftered REM Sleep, Locomotor Activity and Body Temperature in Mice", Society for Neuroscience Abstracts, Vol. 27, No. 1, p. 7, November 2001 FISCHER, W. et al., "Effect of Clobenpropit, A Centrally Acting Histamine H3-Receptor Antagonist, On Electroshock- And Pentylenetetrazol-Induced Seizures In Mice", Journal of Neural Transmission, Vol. 105, pp. 587-599 (1998) LOVENBERG, T.W. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", Molecular Pharmacology, Vol. 55, No. 6, pp. 1101-1107, June 1999	T²
Initials* No.1	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published DUGOVIC, C. et al., "Altered REM Sleep, Locomotor Activity and Body Temperature in Mice", Society for Neuroscience Abstracts, Vol. 27, No. 1, p. 7, November 2001 FISCHER, W. et al., "Effect of Clobenpropit, A Centrally Acting Histamine H3-Receptor Antagonist, On Electroshock- And Pentylenetetrazol-Induced Seizures in Mice", Journal of Neural Transmission, Vol. 105, pp. 587-599 (1998) LOVENBERG, T.W. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", Molecular Pharmacology, Vol. 55, No. 6, pp. 1101-1107, June 1999	T²
Initials* No.1	publisher, city and/or country where published DUGOVIC, C. et al., "Altered REM Sleep, Locomotor Activity and Body Temperature in Mice", Society for Neuroscience Abstracts, Vol. 27, No. 1, p. 7, November 2001 FISCHER, W. et al., "Effect of Clobenpropit, A Centrally Acting Histamine H3-Receptor Antagonist, On Electroshock- And Pentylenetetrazol-Induced Seizures in Mice", Journal of Neural Transmission, Vol. 105, pp. 587-599 (1998) LOVENBERG, T.W. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", Molecular Pharmacology, Vol. 55, No. 6, pp. 1101-1107, June 1999	T²
. /	publisher, city and/or country where published DUGOVIC, C. et al., "Altered REM Sleep, Locomotor Activity and Body Temperature in Mice", Society for Neuroscience Abstracts, Vol. 27, No. 1, p. 7, November 2001 FISCHER, W. et al., "Effect of Clobenpropit, A Centrally Acting Histamine H3-Receptor Antagonist, On Electroshock- And Pentylenetetrazol-Induced Seizures in Mice", Journal of Neural Transmission, Vol. 105, pp. 587-599 (1998) LOVENBERG, T.W. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", Molecular Pharmacology, Vol. 55, No. 6, pp. 1101-1107, June 1999	
m	Abstracts, Vol. 27, No. 1, p. 7, November 2001 FISCHER, W. et al., "Effect of Clobenpropit, A Centrally Acting Histamine H3-Receptor Antagonist, On Electroshock- And Pentylenetetrazol-Induced Seizures In Mice", Journal of Neural Transmission, Vol. 105, pp. 587-599 (1998) LOVENBERG, T.W. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", Molecular Pharmacology, Vol. 55, No. 6, pp. 1101-1107, June 1999	
	Pentylenetetrazol-induced Seizures in Mice", Journal of Neural Transmission, Vol. 105, pp. 587-599 (1998) LOVENBERG, T.W. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", Molecular Pharmacology, Vol. 55, No. 6, pp. 1101-1107, June 1999	
	LOVENBERG, T.W. et al., "Cloning and Functional Expression of the Human Histamine H3 Receptor", Molecular Pharmacology, Vol. 55, No. 6, pp. 1101-1107, June 1999	
	LOVENBERG, T.W. et al., "Cloning of Rat Histamine H3 Receptor Reveals Distinct Species Pharmacological Profiles", Journal of Pharmacology and Experimental Therapeutics, Vol. 293, No. 8, pp. 771-778, June 2000	
	PEREZ-GARCIA, C. et al., "Effects of Histamine H3 Receptor Ligands in Experimental Models of Anxiety and Depression", Psychopharmacology, 142(2):215-20 February 1999	
	TAKAHASHI et al., "Targeted Disruption of H3 Receptors Results in Changes in Brain Histamine Tone Leading to an Obese Phenotype", Journal of Clinical Investigation, Vol. 110, No. 12, pp. 1791-1799 (2002)	
	MASAKI, T. et al., "Targeted Disruption of Histamine H1-Receptor Attenuates Regulatory Effects of Leptin on Feeding, Adiposity, and UCP Family in Mice", Diabetes, Vol. 50, No. 2, pp. 385-391, February 2001	
	TOYOTA et al., "Behavioral Characterization of Mice Lacking Histamine H3 Receptors", Mol. Pharmacol., Vol. 61, No. 2, pp. 389-397, August 2002	
V	TOYOTA, H. et al. "Characterization of Mice Lacking the Histamine H3 Receptor", Society for Neuroscience Abstracts, Vol. 21, No. 1, p. 492 (Nov. 2001)	
mm	YOKOYAMA, H. et al., "Effect of Thioperamide, A Histamine H3 Receptor Antagonist, On Electrically Induced Convulsions In Mice", European Journal of Pharmacology, Vol. 234, pp. 129-133 (1993)	
		_
xaminer	Date Considered 9.28.04	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.